Literature DB >> 11747344

Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: Selective energy depletion.

E V Batrakova1, S Li, W F Elmquist, D W Miller, V Y Alakhov, A V Kabanov.   

Abstract

This paper, for the first time, demonstrates that exposure of cells to the poly(ethylene oxide)-poly(propylene oxide) block copolymer, Pluronic P85, results in a substantial decrease in ATP levels selectively in MDR cells. Cells expressing high levels of functional P-glycoprotein (MCF-7/ADR, KBv; LLC-MDR1; Caco-2, bovine brain microvessel endothelial cells [BBMECs]) are highly responsive to Pluronic treatment, while cells with low levels of P-glycoprotein expression (MCF-7, KB, LLC-PK1, human umbilical vein endothelial cells [HUVECs] C2C12 myoblasts) are much less responsive to such treatment. Cytotoxicity studies suggest that Pluronic acts as a chemosensitizer and potentiates cytotoxic effects of doxorubicin in MDR cells. The ability of Pluronic to inhibit P-glycoprotein and sensitize MDR cells appears to be a result of ATP depletion. Because many mechanisms of drug resistance are energy dependent, a successful strategy for treating MDR cancer could be based on selective energy depletion in MDR cells. Therefore, the finding of the energy-depleting effects of Pluronic P85, in combination with its sensitization effects is of considerable theoretical and practical significance.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11747344      PMCID: PMC2364003          DOI: 10.1054/bjoc.2001.2165

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  26 in total

1.  Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies.

Authors:  E V Batrakova; D W Miller; S Li; V Y Alakhov; A V Kabanov; W F Elmquist
Journal:  J Pharmacol Exp Ther       Date:  2001-02       Impact factor: 4.030

Review 2.  Multidrug resistance in human cancer.

Authors:  L J Goldstein; I Pastan; M M Gottesman
Journal:  Crit Rev Oncol Hematol       Date:  1992       Impact factor: 6.312

3.  ATP assay: ability to distinguish cytostatic from cytocidal anticancer drug effects.

Authors:  H S Garewal; F R Ahmann; R B Schifman; A Celniker
Journal:  J Natl Cancer Inst       Date:  1986-11       Impact factor: 13.506

4.  MTT colorimetric assay for testing macrophage cytotoxic activity in vitro.

Authors:  M Ferrari; M C Fornasiero; A M Isetta
Journal:  J Immunol Methods       Date:  1990-08-07       Impact factor: 2.303

5.  The influence of pluronics and their conjugates with proteins on the rate of oxygen consumption by liver mitochondria and thymus lymphocytes.

Authors:  G P Kirillova; E N Mokhova; V I Dedukhova; A N Tarakanova; V P Ivanova; N V Efremova; I N Topchieva
Journal:  Biotechnol Appl Biochem       Date:  1993-12       Impact factor: 2.431

6.  Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen.

Authors:  J S Lee; K Paull; M Alvarez; C Hose; A Monks; M Grever; A T Fojo; S E Bates
Journal:  Mol Pharmacol       Date:  1994-10       Impact factor: 4.436

7.  Effects of 2-deoxyglucose on drug-sensitive and drug-resistant human breast cancer cells: toxicity and magnetic resonance spectroscopy studies of metabolism.

Authors:  O Kaplan; G Navon; R C Lyon; P J Faustino; E J Straka; J S Cohen
Journal:  Cancer Res       Date:  1990-02-01       Impact factor: 12.701

Review 8.  Multidrug resistance: prospects for clinical management.

Authors:  A Mansouri; K J Henle; W A Nagle
Journal:  SAAS Bull Biochem Biotechnol       Date:  1992-01

9.  The multidrug resistance phenotype: 31P nuclear magnetic resonance characterization and 2-deoxyglucose toxicity.

Authors:  O Kaplan; J W Jaroszewski; R Clarke; C R Fairchild; P Schoenlein; S Goldenberg; M M Gottesman; J S Cohen
Journal:  Cancer Res       Date:  1991-03-15       Impact factor: 12.701

10.  Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport.

Authors:  R Evers; M Kool; A J Smith; L van Deemter; M de Haas; P Borst
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

View more
  60 in total

Review 1.  New technologies for drug delivery across the blood brain barrier.

Authors:  A V Kabanov; E V Batrakova
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

2.  Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.

Authors:  A V Kabanov; H E Gendelman
Journal:  Prog Polym Sci       Date:  2007       Impact factor: 29.190

Review 3.  Nanomedicinal strategies to treat multidrug-resistant tumors: current progress.

Authors:  Xiaowei Dong; Russell J Mumper
Journal:  Nanomedicine (Lond)       Date:  2010-06       Impact factor: 5.307

4.  Block copolymer micelles with acid-labile ortho ester side-chains: Synthesis, characterization, and enhanced drug delivery to human glioma cells.

Authors:  Rupei Tang; Weihang Ji; David Panus; R Noelle Palumbo; Chun Wang
Journal:  J Control Release       Date:  2010-12-29       Impact factor: 9.776

5.  A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction.

Authors:  Juan W Valle; Anne Armstrong; Chris Newman; Valery Alakhov; Grzegorz Pietrzynski; Julie Brewer; Sue Campbell; Pippa Corrie; Eric K Rowinsky; Malcolm Ranson
Journal:  Invest New Drugs       Date:  2010-02-24       Impact factor: 3.850

6.  Structure of polymer micelles close to the solid interface. A grazing incidence small angle neutron scattering study.

Authors:  M Wolff; A Magerl; H Zabel
Journal:  Eur Phys J E Soft Matter       Date:  2005-02-22       Impact factor: 1.890

7.  Gene transfection mediated by ultrasound and Pluronic P85 in HepG2 cells.

Authors:  Fen Wang; Kaiyan Li; Yunchao Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-12

Review 8.  Can nanomedicines kill cancer stem cells?

Authors:  Yi Zhao; Daria Y Alakhova; Alexander V Kabanov
Journal:  Adv Drug Deliv Rev       Date:  2013-10-10       Impact factor: 15.470

9.  Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer.

Authors:  Joseph A Ludwig; Gergely Szakács; Scott E Martin; Benjamin F Chu; Carol Cardarelli; Zuben E Sauna; Natasha J Caplen; Henry M Fales; Suresh V Ambudkar; John N Weinstein; Michael M Gottesman
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

10.  Time and dose dependence of pluronic bioactivity in hyperthermia-induced tumor cell death.

Authors:  Tianyi M Krupka; David Dremann; Agata A Exner
Journal:  Exp Biol Med (Maywood)       Date:  2008-11-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.